Medicamen Biotech------------ Long Plan
Обновлено
Medicamen Biotech Ltd develops and markets a wide range of branded and generic formulations in the pharmaceutical industry.[1]
KEY POINTS
Product Offerings
The company manufactures a wide range of formulations in the form of tablets, capsules, liquid syrup, dry syrup (beta lactum & non-beta lactum) ointment and Oral rehydration solution (ORS).[1]
Therapeutic Areas
Its key therapeutic areas are antibiotic, antimalarial, antidiarrheal, antituberculosis & general pain management.[2]
Geographical Presence
The company has geographical presence across India, S.E. Asia, Africa, Brazil, South Asia, CIS, Australia and others.[3]
Entry into Oncology Business
The company entered into oncology area by establishing its 3rd manufacturing plant in FY21.[4] The plant will manufacture oncology products such as tablets, capsules, injectables and lyophilizers. The facility is USFDA and EU compliant.[5]
Manufacturing Capabilities
Presently, the company owns and operates 3 manufacturing facilities; 2 in Haridwar, Uttarakhand and 1 in Bhiwadi, Rajasthan.[5] The facilities are certified by authorities like WHO, ANVISA (Brazil), NAFDAC, MCAZ, DACA, etc.[6]
Upgradation of Facility - In Jan 2021, the company announced partial shutdown of its Bhiwadi facility for upgradation at 3 areas of the plant.[7]
R&D Capabilities
It has a strength of ~45 R&D employees.[8] It has spent ~20 crores towards R&D during FY18-20 and has filed 15 patents till FY20 with various authorities. [9]
Acquisition of Opal Pharmaceuticals
During FY20, the company acquired OPAL Pharma; an Australian pharmaceutical company and medical supplies distributor.[10] It was acquired for ~2.3 crores INR. (420,000 AUD). [11]
Market Cap
₹ 1,200 Cr.
Current Price
₹ 982
High / Low
₹ 999 / 390
Stock P/E
77.3
Book Value
₹ 116
Dividend Yield
0.10 %
ROCE
12.7 %
ROE
9.73 %
Face Value
₹ 10.0
KEY POINTS
Product Offerings
The company manufactures a wide range of formulations in the form of tablets, capsules, liquid syrup, dry syrup (beta lactum & non-beta lactum) ointment and Oral rehydration solution (ORS).[1]
Therapeutic Areas
Its key therapeutic areas are antibiotic, antimalarial, antidiarrheal, antituberculosis & general pain management.[2]
Geographical Presence
The company has geographical presence across India, S.E. Asia, Africa, Brazil, South Asia, CIS, Australia and others.[3]
Entry into Oncology Business
The company entered into oncology area by establishing its 3rd manufacturing plant in FY21.[4] The plant will manufacture oncology products such as tablets, capsules, injectables and lyophilizers. The facility is USFDA and EU compliant.[5]
Manufacturing Capabilities
Presently, the company owns and operates 3 manufacturing facilities; 2 in Haridwar, Uttarakhand and 1 in Bhiwadi, Rajasthan.[5] The facilities are certified by authorities like WHO, ANVISA (Brazil), NAFDAC, MCAZ, DACA, etc.[6]
Upgradation of Facility - In Jan 2021, the company announced partial shutdown of its Bhiwadi facility for upgradation at 3 areas of the plant.[7]
R&D Capabilities
It has a strength of ~45 R&D employees.[8] It has spent ~20 crores towards R&D during FY18-20 and has filed 15 patents till FY20 with various authorities. [9]
Acquisition of Opal Pharmaceuticals
During FY20, the company acquired OPAL Pharma; an Australian pharmaceutical company and medical supplies distributor.[10] It was acquired for ~2.3 crores INR. (420,000 AUD). [11]
Market Cap
₹ 1,200 Cr.
Current Price
₹ 982
High / Low
₹ 999 / 390
Stock P/E
77.3
Book Value
₹ 116
Dividend Yield
0.10 %
ROCE
12.7 %
ROE
9.73 %
Face Value
₹ 10.0
Заметка
triggered , added some units @ 880
Отказ от ответственности
Все виды контента, которые вы можете увидеть на TradingView, не являются финансовыми, инвестиционными, торговыми или любыми другими рекомендациями. Мы не предоставляем советы по покупке и продаже активов. Подробнее — в Условиях использования TradingView.